Could a single treatment lower heart disease risk by up to 90%?

At Scribe, we're engineering #CRISPR gene editing and epigenetic silencing therapies that target major drivers of cardiometabolic disease. Our CEO @benjaminloakes.bsky.social recently shared our progress at #TCT2025.

TCTMD’s Top 10 Most Popular Stories for November 2025 Drugs, devices, and even coffee made it into the mix as we move from a busy meeting season to the restful holidays ahead.

The editorial team reviews the top stories from the month of November, with the most popular coming from #TCT2025 and #AHA2025. Read them all now on TCTMD: www.tctmd.com/news/tctmds-...

Webinars & Podcasts - American College of Cardiology Webinars from the Interventional Section.

Did you miss #TCT2025 or want hot takes? 🔥 Check out the webinar posted here www.acc.org/Membership/S...

In the latest On Record, Caitlin E. Cox and Kenneth Rosenfield discuss the roadblocks and solutions to lack of access in the management of pulmonary embolism during #TCT2025. Watch it now: www.tctmd.com/videos/on-re...

In this episode of Fellows Forum, @yaelmaxwell.bsky.social talks with Grant Reed, Angelo Oliva, and Raunak M. Nair on how they broach difficult conversations with patients and educate other practitioners to do them effectively and empathically. #TCT2025 www.tctmd.com/videos/hard-...

‘Investing’ in CTOs With Staged PCI Seems to Pay Off in Safety Gains The single-arm INVEST-CTO study showed high procedural success with a two-part intervention, but questions remain.

A two-part staged intervention consisting of an initial modification and a secondary completion procedure may improve procedural success and safety outcomes for patients with anatomically high-risk CTO lesions, according to the INVEST-CTO study. #TCT2025 www.tctmd.com/news/investi...

During #TCT2025, @yaelmaxwell.bsky.social, Brittany Zwischenberger, and Milan Milojevic talk about the continuing optimization of CABG and the latest advancements to come. Watch the latest On Record now: www.tctmd.com/videos/on-re...

What Makes MedTech Great—or Not—and Envisioning Its Future Experts gathered at the TCT MedTech Innovation Forum to discuss successes, failures, barriers, and solutions in healthcare.

Is MedTech already great or is there room for improvement? During the TCT MedTech Innovation Forum, a panel of experts discussed successes, failures, and what future innovations could look like. #TCT2025 www.tctmd.com/news/what-ma...

📺 Jetzt ansehen: #AHA2025 / #TCT2025 Kongress-Update ab sofort als On-Demand-Video verfügbar! Erfahren Sie alles über aktuelle Studien aus den Fachbereichen: 🫀 Interventioneller Kardiologie,⚡ Rhythmologie, 💊 Herzinsuffizienz & 💪 Prävention
➡️ herzmedizin.de/fuer-...
#Kardiologie #CardioSky

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES The trial showed no difference in device-related thrombosis, but there were fewer adverse events with DOACs.

DOACs may have fewer adverse events than DAPT after left atrial appendage closure, making it a safer option, according to data from the ANDES trial presented at #TCT2025. Read more here: www.tctmd.com/news/doac-ma...

AI-ECG Finds STEMI Faster, Cuts False-Positive Cath Lab Activations Physicians will remain in the loop, but AI can “turbocharge and augment our abilities,” an emergency medicine physician says.

For the detection of angiographically confirmed STEMI, AI-ECG outperformed standard processes, slashing false-positive cath lab activations, according to a retrospective study. More here:
#TCT2025 www.tctmd.com/news/ai-ecg-...

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time Bioadaptor was designed to restore normal vessel function and reduce late stent-related complications. It’s working so far.

Using a novel “unlocking” coronary device may reduce the risk of target lesion failure between 6 months and 2 years by nearly 50%, based on an analysis from the INFINITY-SWEDEHEART trial presented at this year's #TCT2025. www.tctmd.com/news/infinit...

PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats The saphenous vein grafts treated in the RCT were relatively straightforward, while the native vessels were largely CTOs.

Performing PCI to open up the graft for patients with failed SVGs after CABG reduces the rate of major CV events compared with intervening on the bypassed native coronary artery, according to results from the PROCTOR trial. #TCT2025 www.tctmd.com/news/proctor...

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI The everolimus scaffold, which had mostly disappeared by 3 years, was still associated with fewer reinterventions than PTA.

Three-year data from the LIFE-BTK trial shows that a drug-eluting resorbable scaffold continues to keep many patients with below-the-knee chronic limb-threatening ischemia free from repeat procedures even after it dissolves. #TCT2025 www.tctmd.com/news/life-bt...

Tendyne Safely Reduces MR in Patients With Severe Calcification: SUMMIT-MAC The device, which is delivered transapically, represents an option for very sick patients who previously have had none.

TMVR with the Tendyne system successfully treats MR or stenosis complicated by severe MAC, improving heart failure symptoms and quality of life, according to findings from the SUMMIT-MAC study presented at #TCT2025. More here: www.tctmd.com/news/tendyne...

PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States Reaching participants through retail pharmacies, the study speaks to how much VHD goes underrecognized—with a few surprises.

In the US, 10 million older people, two-thirds of them women, have mild or greater valvular heart disease, based on data from the PREVUE-VALVE study. To optimize screening, "we need to understand the true prevalence of VHD–how much there is," said David Cohen. #TCT2025
www.tctmd.com/news/prevue-...

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve durability.

Longer-term results from the PARTNER 3 trial presented at #TCT2025 showed that both surgery and TAVI continued to have stable outcomes and no signs of valve failure in low-risk patients with symptomatic severe aortic stenosis at 7 years. www.tctmd.com/news/partner...

During #TCT2025 in San Francisco, @mmamas1973.bsky.social and Evald Christiansen discuss the late-breaking NOBLE trial. Watch the full episode of Beyond the Data: www.tctmd.com/videos/beyon...

ECG-reading AI better detects severe heart attacks in emergency setting AI-based ECG interpretation detected more STEMIs and had fewer false positives

In #emergency settings, #AI to analyze #ECG data can improve detection of severe #heartattack, including those with unconventional symptoms, or atypical patterns, and reduced false positives, finds a new study published in @jaccjournals.bsky.social and presented at @crfheart.bsky.social's #TCT2025.

At #TCT2025 in San Francisco, @mmamas1973.bsky.social and Josep Rodés-Cabau discuss short-term anticoagulation vs DAPT post-LAAO in this episode of Beyond the Data. Watch it now: www.tctmd.com/videos/beyon...

More Data on Tricuspid Valve Interventions Reassure, yet Questions Remain The real-world Evoque and new TRILUMINATE findings provide an “extension” from the pivotal trials, Dharam Kumbhani says.

Supporters of transcatheter tricuspid valve interventions for severe TR are reassured by new real-world and extended trial data, presented at this year's #TCT2025. But longer-term follow up is still needed to answer continued questions on safety and efficacy. www.tctmd.com/news/more-da...

Trials Bolster Alternatives to Intravascular Lithotripsy for Calcified Lesions Lower-cost cutting and noncompliant balloons were noninferior to Shockwave IVL for short-term stent outcomes.

The use of cutting and noncompliant balloons for lesion preparation may provide results similar to Shockwave intravascular lithotripsy in patients with significant coronary lesion calcification who require PCI. #TCT2025 www.tctmd.com/news/trials-...

STEMI Outcomes Not Helped by Upfront Instantaneous Wave-Free Ratio, Multivessel PCI Deferred stress cardiac MRI-guided PCI ofnon-culprit lesions sufficed in iMODERN

For patients with STEMI and multivessel disease, there was no clinical benefit to a strategy of finding and treating all nonculprit lesions during the index cath lab session, according to the iMODERN trial of over 1,000 patients. #TCT2025
www.medpagetoday.com/meetingcover...

Suzanne Baron and Matthias Bossard sit down with Mamas Mamas (@mmamas1973.bsky.social) to discuss the Short-Cut and VICTORY trials presented earlier this week at #TCT2025. Watch the full video: tctmd.com/videos/beyon...

SHORT-CUT Trial

📊 Just in from #TCT2025! In the SHORT-CUT trial, WOLVERINE™ Cutting Balloon was noninferior to intravascular lithotripsy (IVL) for post-PCI MSA at site of max calcium and cut total procedural cost by $3,632 ($9,409 vs $13,051; p < 0.001).

Mechanical Thrombectomy Outshines Anticoagulation Alone in STORM-PE (UPDATED) The first of its kind RCT in acute intermediate-high-risk PE used a surrogate endpoint, but more data are on the horizon.

Patients with acute intermediate-high-risk PE who undergo mechanical thrombectomy have a greater reduction in the RV/LV ratio at 48 hours than those treated with anticoagulation alone, according to results from the first-of-its-kind STORM-PE RCT. #TCT2025 www.tctmd.com/news/mechani...

ICYMI: Interventional cardiology was in the spotlight at #TCT2025! FAME 3, DOSE Trials explore cost-effectiveness, operator radiation risk after coronary procedures.

📰 Find all the insights in the ACC News story ➡️ https://bit.ly/4nzLZaf #JACC @jaccjournals.bsky.social

Congratulations to Dr. Miho Fukui on her presentation at #TCT2025 on aortic valve area reduction, a novel, personalized metric for assessing aortic stenosis severity. 👏

The value of % aortic valve reduction beyond conventional TTE parameters will be presented at London Valves 2025.

TTVR Remains Safe, Effective in Presence of CIED Leads The rate of death or HF hospitalization was not influenced by the presence of leads after accounting for comorbidity burden.

The need for a cardiac implantable electronic device (CIED) before or after undergoing TTVR does not have a significant impact on all-cause death or hospitalization for HF at 1 year, according to an analysis of TRISCEND and TRISCEND II. #TCT2025 www.tctmd.com/news/ttvr-re...

We're covering #TCT2025 -- read the thread below to catch up on everything you missed from this year's meeting! ⬇️✨